Evicenter
MarkdownMedical informationP&T meetings
Envudeucitinib (ESK-001)

Moderate-to-severe plaque psoriasis

Also known as FTP-637
Manufacturer
Alumis
Launch
Not announced
Last updated
277 sources

Section 3 of 6

Product information and disease description

406 evidence topics · 220 sources

Product description

Phase of product development

Launch

No evidence found.

ONWARD1 and ONWARD2 topline data expected in the first half of 2026, November 2024, superseded in March 2025
Patent protection: composition of matter, crystalline and salt forms, and methods of treatment

“In regard to envu and A-005, we own one patent family with claims directed to composition of matter and methods of use that includes five issued U.S. patents, one pending U.S. patent application, over fifteen granted foreign patents in Europe (each validated in over 35 countries), and certain other countries, and over 10 foreign patent applications pending in various jurisdictions, such as Europe and Japan.” (opens the source at this quote in a new tab)

“Not accounting for any patent term adjustment or extensions or terminal disclaimers, and assuming that all applicable annuity and/or maintenance fees are paid timely, the issued patents, and, if granted, the pending patent applications in this family, are expected to expire in 2039.” (opens the source at this quote in a new tab)

“We also own three patent families with claims directed to crystalline and salt forms of envu, which includes three pending U.S. applications, and over 30 foreign patent applications pending in various jurisdictions such as Europe and Japan.” (opens the source at this quote in a new tab)

“Not accounting for any patent term adjustment or extension and assuming that all applicable annuity and/or maintenance fees are paid timely, the patent applications, if issued, and any patent applications claiming the benefit of these PCT applications, if issued, will be expected to expire in 2043.” (opens the source at this quote in a new tab)

“We own one patent family with claims directed to methods of treating a TYK2-mediated disease using envu, that includes a pending U.S. application and over 10 foreign applications pending in various jurisdictions such as Europe and Japan.” (opens the source at this quote in a new tab)

Product information

Generic, brand name and therapeutic class of product
Substance names and development codes in the FDA substance registration record
FieldQuoted record
Preferred substance name“ENVUDEUCITINIB”
International Nonproprietary Name synonym“envudeucitinib [INN]”
Development code synonym“ESK-001”
Second development code synonym“FTP-637”
Systematic chemical name synonym“N-[4-[2-methoxy-3-[1-(trideuteriomethyl)-1,2,4-triazol-3-yl]anilino]-5-(3,3,3-trideuteriopropanoyl)-2-pyridinyl]cyclopropanecarboxamide”
Dosage forms and strengths
Average sales price and wholesale acquisition cost

Not applicable.

American hospital formulary service (AHFS), or other drug classification
Proposed International Nonproprietary Name and class description
Nomenclature and drug dictionary entries in the FDA substance registration record
FieldQuoted record
Substance type“INGREDIENT SUBSTANCE”
Molecular formula“C22H24N6O3”
United States Adopted Name synonym“ENVUDEUCITINIB [USAN]”
WHO Drug Dictionary synonym“ESK 001 [WHO-DD]”
Indication
Pharmacology
Mechanism of action
Allosteric inhibition of TYK2 through the pseudokinase (JH2) domain
Human whole-blood inhibitory concentrations by cytokine pathway
Stimulus (kinase pathway)Human whole blood IC50 (nM)
IFNα (TYK2)“104”
IL-12 (TYK2)“149”
IL-2 (JAK1/JAK3)“>30,000”
TPO (JAK2)“>30,000”
Pharmacodynamics
Skin tape-strip transcriptomics and proteomics in a STRIDE subgroup
Pharmacokinetics
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions

Not applicable.

Special populations
Drug/Drug, drug/disease interactions
Effects of other drugs on Envudeucitinib
Effects of Envudeucitinib on other drugs
Dosing and administration
Dosage
Administration
Access and distribution
Launch preparation and commercial infrastructure
Co-prescribed/Concomitant therapies
Prohibited treatments and washout periods in the STRIDE protocol
Effect of Envudeucitinib on quality measures
MIPS Quality ID 485: description, measure type, denominator, and numerator for itch severity
HEDIS and NCQA measures for psoriasis

No evidence found.

Product-specific effect of envudeucitinib on quality measure performance

No evidence found.

Product comparison
Dosage forms, dosing frequency, and administration: deucravacitinib, apremilast, and icotrokinra labels
Infection, hepatitis, and immunization requirements: deucravacitinib and icotrokinra labels
Laboratory and clinical monitoring: deucravacitinib, apremilast, and icotrokinra labels
Pregnancy, lactation, pediatric use, and geriatric use: deucravacitinib, apremilast, and icotrokinra labels
Renal and hepatic impairment: deucravacitinib, apremilast, and icotrokinra labels
Selectivity for TYK2 over JAK1, JAK2, and JAK3 across allosteric TYK2 inhibitors
Duration of TYK2 inhibition across the dosing interval and dosing frequency of TYK2 inhibitors
Efficacy and tolerability of deucravacitinib relative to apremilast and injectable biologics in narrative reviews
Head-to-head trial: risankizumab versus deucravacitinib in biologic-naive moderate psoriasis, week 16

“IMMpactful is a phase 4 multicenter, randomized, open-label, efficacy assessor-blinded, active comparator study examining the safety and efficacy of RZB compared with DEU in patients with moderate psoriasis who are candidates for systemic therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In period A, patients either received a single subcutaneous injection of RZB 150 mg on day 1 and week 4 or oral DEU 6 mg daily.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Of the 393 patients enrolled in IMMpactful, 131 were randomized to RZB and 262 to DEU (1 patient did not receive study drug) in period A (Fig. 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“A significantly higher proportion of patients treated with RZB achieved PASI 90 (57.3% versus 22.9%), sPGA 0/1 (80.2% versus 39.7%), PASI 100 (27.5% versus 6.5%), and sPGA 0 (27.5% versus 6.9%) compared with patients treated with DEU at week 16 (P < 0.0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“A greater proportion of patients treated with RZB (64.1% [95% CI 55.9%, 72.3%]) achieved DLQI 0/1 compared with patients treated with DEU (30.5% [95% CI 25.0%, 36.1%]) (Fig. 5A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In period A, TEAEs were reported in 33.6% of patients treated with RZB compared with 42.9% of patients treated with DEU.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“One potential limitation is that this study employs an open-label design rather than a double-blinded design.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“AbbVie funded this study (NCT06333860) and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the publication.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Network meta-analyses of TYK2 inhibitors and other oral agents
Absence of head-to-head trials and formal indirect comparisons that include envudeucitinib

Place of product in therapy

Disease description

Definition and etiology
Epidemiology
Incidence of Moderate-to-severe plaque psoriasis
Prevalence of Moderate-to-severe plaque psoriasis
Natural history, survival, and mortality
Pathophysiology
Diagnosis
Clinical presentation - signs and symptoms
Long-term morbidity
Burden of Moderate-to-severe plaque psoriasis
Humanistic burden and health-related quality of life
Itch, pain, fatigue, Dermatology Life Quality Index, and EQ-VAS by severity: U.S. Corrona Psoriasis Registry, 1,529 patients on systemic therapy

“The Corrona Psoriasis Registry is an independent, prospective observational cohort launched in April 2015 in collaboration with the National Psoriasis Foundation, with a target enrolment of 10 000 patients with psoriasis from 200 sites throughout the USA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“1529 adult patients with psoriasis being treated with biological or non-biological systemic psoriasis treatment by 31 May 2016.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“As of 31 May 2016, 1529 patients were enrolled in the registry; the mean age was 50.6 years and 47% were female.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“BSA percentages were categorised as mild (0%–5%), moderate (>5%–10%), severe (>10%–15%) and very severe (>15%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Across BSA categories, mean fatigue scores ranged from 26.5 to 40.2, itching was 24.7 to 55.7 and pain was 15.2 to 41.7. Among IGA categories, mean fatigue scores ranged from 21.9 to 41.8, itching was 12.1 to 57.3 and pain was 7.4 to 44.3.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Across BSA and IGA categories, mean DLQI scores ranged from 5.2 to 10.2 and 4.3 to 9.7, respectively. Mean EQ-VAS scores ranged from 62.9 (very severe) to 76.4 (mild) across BSA categories and 62.1 (severe) to 78.8 (clear/almost clear) across IGA categories, with higher scores indicating better health.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Overall DLQI and EQ-VAS scores also worsened with disease severity (p<0.05 for each level of BSA and IGA) (table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Emotional wellbeing, quality of life, self-image, and stigma: U.S. online survey of 793 patients, 2020 to 2021

“In brief, the study was a cross-sectional, quantitative online survey conducted in the USA between 12 November 2020 and 19 May 2021 and comprised a 5-min eligibility screener followed by a 25-min online questionnaire.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“This analysis included 793 US patients with psoriasis; 43% also had PsA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Psoriasis negatively affected emotional well-being and quality of life (QoL) in the majority of patients (87% and 91%, respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Patients stated that their skin symptoms made them feel unattractive (42%), less confident about themselves (37%), ashamed of their skin (35%), depressed (33%), or ashamed of their body (30%; Supplementary Material Fig. S5b).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Many patients also noted that they had experienced stigma and discrimination, such as people not understanding the impact the disease had on the patient’s life (36%), being asked if they were contagious (36%), and being stared at in public (34%) (Supplementary Material Fig. S5a).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Economic burden and healthcare resource utilization
All-cause costs and resource use in moderate-to-severe psoriasis versus matched controls: OptumHealth claims, 2007 to 2012

“Adults aged 18-64 years with at least 2 PsO diagnoses (ICD-9-CM code 696.1) were identified in the OptumHealth Reporting and Insights claims database from January 2007 to March 2012. Moderate-to-severe PsO patients were identified as those receiving ≥ 1 systemic therapy or phototherapy during the 12-month study period following the index date (randomly selected date after the first PsO diagnosis). Controls were free of PsO and psoriatic arthritis (PsA) and were matched 1:1 with PsO patients on age, gender, and geographic region.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“All-cause health care costs and PsO-related costs (PsO treatment costs and PsO-related medical costs, calculated for moderate-to-severe PsO patients only) were calculated as reimbursed amounts from payers and were adjusted to 2012 U.S. dollars using the medical care component of the Consumer Price Index.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Compared with controls, PsO patients incurred higher annual total health care costs per patient ($22,713 vs. $4,993, adjusted cost difference [ACD] = $18,960; P < 0.001), driven by significantly higher costs in all-cause medications ($14,698 vs. $1,101, ACD = $13,990; P < 0.001) and all-cause medical services ($8,015 vs. $3,892, ACD = $3,895; P = 0.002; Figure 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“During the 12-month study period, the moderate-to-severe PsO patients incurred an average of $13,731 PsO-related costs, a majority of which were attributed to treatment costs for systemic PsO therapies ($12,958) that included biologics, nonbiologics, and phototherapies (Table 5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In addition, PsO patients were more likely to incur all-cause medical services, including any inpatient admissions (9.3% vs. 6.4%, aOR = 1.3), ER visits (21.4% vs. 16.4%, aOR = 1.3), and outpatient visits (99.0% vs. 84.5%, aOR = 29.3; all P < 0.001). On average, PsO patients had more inpatient admissions (0.15 vs. 0.09, aIRR = 1.3; P = 0.001), ER visits (0.40 vs. 0.27, aIRR = 1.3; P < 0.001), and outpatient visits (20.46 vs. 8.41, aIRR = 2.4; P < 0.001). PsO patients also spent more hospitalization days (1.03 vs. 0.55, aIRR = 1.9; P < 0.001) than controls.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Costs and outpatient encounters by severity among biologic-treated patients: linked U.S. claims and electronic health records

“To describe healthcare resource utilization (HCRU) and costs among biologic-treated psoriasis patients in the US, overall and by disease severity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“IQVIA PharMetrics Plus administrative claims data were linked with Modernizing Medicine Data Services Electronic Health Record data and used to select adult psoriasis patients between April 1, 2010 and December 31, 2014.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“This study identified 2,130 biologic-treated psoriasis patients: 282 (13%) had mild, 116 (5%) moderate, and 49 (2%) severe disease; 1,683 (79%) could not be classified.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Relative to mild psoriasis patients, patients with moderate or severe disease had more median all-cause outpatient encounters (28.0 [mild] vs 32.0 [moderate], 36.0 [severe]), more median psoriasis-related outpatient encounters (6.0 [mild] vs 7.5 [moderate], 8.0 [severe]), and a higher proportion of overall claims for medications that were psoriasis-related (28% [mild] vs 37% [moderate], 34% [severe]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Relative to mild psoriasis patients, patients with moderate or severe disease had higher median all-cause total costs ($37.7k [mild] vs $42.3k [moderate], $49.3k [severe]), higher median psoriasis-related total costs ($32.7k [mild] vs $34.9k [moderate], $40.5k [severe]), higher median all-cause pharmacy costs ($33.9k [mild] vs $36.5k [moderate], $36.4k [severe]), and higher median psoriasis-related pharmacy costs ($32.2k [mild] vs $33.9k [moderate], $35.6k [severe]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Work productivity loss and annual indirect costs by severity: Adelphi survey in the U.S. and five European countries

“To estimate total WPL and related indirect costs, and identify predictors of WPL associated with psoriasis severity in France, Germany, Spain, the U.K. and Italy (EU5) and the U.S.A.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Data from the 2015 Adelphi Real World Psoriasis Disease Specific Programme, analysed for absenteeism, presenteeism and total WPL, were quantified (0–100%) from participants who completed the Work Productivity and Activity Impairment (WPAI) instrument.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Of the 936 respondents (29·6% U.S.A., 70·4% EU5) who completed the WPAI, 32·6%, 40·7% and 26·6% had mild [body surface area (BSA) 0–2%], moderate (BSA 3–10%) and severe (BSA > 10%) psoriasis, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Mean percentages of total WPL for respondents with mild, moderate and severe psoriasis were 10·1%, 18·9% and 29·4%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Mean annual indirect costs due to WPL per patient were highest in the U.S.A. (9591 U.S. dollars, 95% CI 8407–10 775), reflecting a particularly high contribution from presenteeism (9173 U.S. dollars, 95% CI 8063–10 283).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Economic impact of Moderate-to-severe plaque psoriasis on families
Extra housework, psychological pressure, and social disruption among 63 relatives and partners

“Thirty-three subjects were interviewed and 30 replied by postal questionnaire. Twenty-eight of the 63 subjects were relatives (seven men and 21 women) and 35 were partners (16 men and 19 women).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Seventy per cent stated that the treatment of their relative or partner resulted in them having to spend extra time on housework; 57% described psychological pressures including anxiety, being upset and being worried about the patient's future; 55% described social disruption due to lack of social confidence either because of embarrassment or because of the time required for care duties; 44% described limitations to holiday plans, sport and leisure activities and evenings out; 37% described limitations on their daily activities such as shopping, work and time spent with other family members; 37% felt that their close relationships had deteriorated. Only 8% described no effect at all on their QoL.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The QoL of the relatives and partners (number of categories affected) was more closely related to the patients' QoL (DLQI: r = 0.77, P < 0.001; PDI: r = 0.67, P < 0.001) than to the objective disease severity scores (PASI: r = 0.34, P < 0.05).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Economic impact of diagnostic testing

Not applicable.

Approaches to treatment

Current treatment options and standard of care
Topical therapies
Phototherapy
Conventional systemic therapies
PDE4 inhibitors
Week 16 clinical response in Trials PSOR-1 and PSOR-2: apremilast label
Endpoint at Week 16, n (%)PSOR-1 placebo (N = 282)PSOR-1 OTEZLA 30 mg BID (N = 562)PSOR-2 placebo (N = 137)PSOR-2 OTEZLA 30 mg BID (N = 274)
PASI-75“15 (5.3)”“186 (33.1)”“8 (5.8)”“79 (28.8)”
sPGA of clear or almost clear“11 (3.9)”“122 (21.7)”“6 (4.4)”“56 (20.4)”
Adverse reactions through week 16 in adults with moderate to severe plaque psoriasis: apremilast label
Adverse reaction, n (%)Placebo (N = 506)OTEZLA 30 mg BID (N = 920)
Diarrhea“32 (6)”“160 (17)”
Nausea“35 (7)”“155 (17)”
Tension headache“21 (4)”“75 (8)”
Headache“19 (4)”“55 (6)”
Network meta-analysis design: bayesian analysis of short-term PASI response at 10 to 16 weeks in 60 trials and a traditional meta-analysis at 44 to 60 weeks

“A bayesian network meta-analysis was conducted to estimate short-term PASI response rates; to account for variation across trials, an ordinal model that adjusted for reference arm response was implemented.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The long-term PASI rates were estimated via a traditional meta-analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In a network meta-analysis of 60 clinical trials for short-term efficacy, brodalumab, guselkumab, ixekizumab, and risankizumab-rzaa had the highest Psoriasis Area and Severity Index response rates at 10 to 16 weeks from baseline.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“A total of 60 trials meeting all inclusion criteria were included in the base-case NMA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The base-case analysis included all biologics, apremilast, and dimethyl fumarate.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The estimated PASI response rates were summarized using posterior medians and their associated 95% credible intervals (CrIs).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

TYK2 inhibitors
Trial PSO-1 efficacy versus placebo and apremilast: deucravacitinib label
Endpoint, n (%)SOTYKTU (N=330)Placebo (N=166)Apremilast (N=168)
sPGA 0/1, Week 16“178 (54)”“12 (7)”“54 (32)”
PASI 75, Week 16“193 (58)”“21 (13)”“59 (35)”
PASI 90, Week 16“118 (36)”“7 (4)”“33 (20)”
Endpoint at Week 24, Trial PSO-1, n (%)SOTYKTU (N=330)Apremilast (N=168)
PASI 75“228 (69)”“64 (38)”
PASI 90“140 (42)”“37 (22)”
Adverse reactions through week 16 in Trials PSO-1 and PSO-2: deucravacitinib label
Adverse reaction, n (%)SOTYKTU 6 mg once daily (N=840)Placebo (N=419)
Upper respiratory infections“161 (19.2)”“62 (14.8)”
Blood creatine phosphokinase increased“23 (2.7)”“5 (1.2)”
Herpes simplex“17 (2)”“1 (0.2)”
Mouth ulcers“16 (1.9)”“0 (0.0)”
Folliculitis“14 (1.7)”“0 (0.0)”
Guideline statements: deucravacitinib infections, herpes zoster, laboratory changes, and malignancies
Oral IL-23 receptor antagonist peptides
Trial PSO-2 efficacy versus placebo and deucravacitinib: icotrokinra label
Endpoint, Trial PSO-2, n (%)ICOTYDE (N=320)Placebo (N=81)Deucravacitinib (N=322)
IGA 0 or 1 with ≥2-grade improvement, Week 16“227 (71)”“7 (9)”“177 (55)”
PASI 90, Week 16“184 (58)”“1 (1)”“111 (34)”
Endpoint at Week 24, Trial PSO-2, n (%)ICOTYDE (N=320)Deucravacitinib (N=322)
PASI 90“208 (65)”“141 (44)”
ICONIC-ADVANCE 1 and 2: icotrokinra versus placebo and deucravacitinib, week 16 and week 24
ICONIC-LEAD: icotrokinra versus placebo in adults and adolescents, week 16

“Participants were assigned in a 2:1 ratio to receive icotrokinra at a dose of 200 mg once daily through week 24 or placebo through week 16 followed by transition to icotrokinra.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“At week 16, a total of 65% of the participants receiving icotrokinra and 8% of those receiving placebo had an IGA 0/1 response, and 50% and 4%, respectively, had a PASI 90 response (P<0.001 for both comparisons).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Complete clearance of skin at week 16 was significantly more likely with icotrokinra than with placebo (IGA score of 0, 33% vs. 1%; PASI 100 response [100% reduction from baseline in the PASI score], 27% vs. <1%; P<0.001 for both comparisons).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The percentage of participants with at least one adverse event through week 16 was 49% in each group; the most common adverse events in each group were nasopharyngitis and upper respiratory tract infection.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“(Funded by Johnson & Johnson; ICONIC-LEAD ClinicalTrials.gov number, NCT06095115.)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

TNF inhibitors
Decision aid: TNF inhibitors
AgentRoughly what proportion of people are clear or nearly clear (PASI 90) in the first 6 months?What is the likelihood of staying on this treatment for more than 1 year?
Adalimumab“31%”“74–76% chance”
Certolizumab pegol“24%”“Not known at present”
Etanercept“18%”“67–73% chance”
Infliximab“91%”“54–74% chance”
Network meta-analysis: infliximab and other TNF inhibitors
IL-12/23 inhibitors
Ustekinumab: Ps STUDY 1 and Ps STUDY 2 outcomes at week 12
Outcome at Week 12, n (%)Ps STUDY 1 placebo (N=255)Ps STUDY 1 STELARA 45 mg (N=255)Ps STUDY 1 STELARA 90 mg (N=256)Ps STUDY 2 placebo (N=410)Ps STUDY 2 STELARA 45 mg (N=409)Ps STUDY 2 STELARA 90 mg (N=411)
PASI 75 response“8 (3%)”“171 (67%)”“170 (66%)”“15 (4%)”“273 (67%)”“311 (76%)”
PGA of cleared or minimal“10 (4%)”“151 (59%)”“156 (61%)”“18 (4%)”“277 (68%)”“300 (73%)”
Decision aid: ustekinumab
AgentRoughly what proportion of people are clear or nearly clear (PASI 90) in the first 6 months?What is the likelihood of staying on this treatment for more than 1 year?
Ustekinumab“34%”“84–86% chance”
Network meta-analysis: ustekinumab compared with other biologics and oral agents
TreatmentPASI 75 at 10 to 16 weeks, % (95% CrI)PASI 90 at 10 to 16 weeks, % (95% CrI)PASI 100 at 10 to 16 weeks, % (95% CrI)
Ustekinumab, 45 mg ≤100 kg, 90 mg >100 kg“69.7 (66.3-73.1)”View highlighted excerpt for this quote“43.9 (40.2-47.9)”View highlighted excerpt for this quote“16.7 (14.4-19.3)”View highlighted excerpt for this quote
IL-17 inhibitors
Brodalumab versus ustekinumab and placebo: week 12 outcomes in Trial 2
Outcome at Week 12, Trial 2, n (%)SILIQ 210 mg Q2W (N=612)Ustekinumab (N=300)Placebo (N=309)
PASI 75 response“528 (86)”“210 (70)”“25 (8)”
PASI 100 response“272 (44)”“65 (22)”“2 (1)”
BE RADIANT: bimekizumab versus secukinumab, PASI 100 at weeks 16 and 48 and oral candidiasis

“A total of 1005 patients were screened and 743 were enrolled; 373 patients were assigned to receive bimekizumab and 370 to receive secukinumab.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“At week 16, a total of 230 patients (61.7%) in the bimekizumab group and 181 (48.9%) in the secukinumab group had a 100% reduction from baseline in the PASI score (PASI 100) (adjusted risk difference, 12.7 percentage points; 95% confidence interval [CI], 5.8 to 19.6); bimekizumab was shown to be noninferior and superior to secukinumab (P<0.001 for noninferiority and superiority).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“At week 48, a total of 250 patients (67.0%) treated with bimekizumab had a PASI 100 response, as compared with 171 patients (46.2%) treated with secukinumab (adjusted risk difference, 20.9 percentage points; 95% CI, 14.1 to 27.7; P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Oral candidiasis occurred more often with bimekizumab (72 patients, 19.3%) than with secukinumab (11 patients, 3.0%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“(Funded by UCB Pharma; BE RADIANT ClinicalTrials.gov number, NCT03536884.)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Decision aid: IL-17 inhibitors
AgentRoughly what proportion of people are clear or nearly clear (PASI 90) in the first 6 months?What is the likelihood of staying on this treatment for more than 1 year?
Bimekizumab“54%”“Not known at present”
Brodalumab“50%”“Not known at present”
Ixekizumab“53%”“77–83% chance”
Secukinumab“47%”“80–83% chance”
Network meta-analysis: anti-IL-17 agents compared with placebo and with other classes
IL-23 inhibitors
Decision aid: IL-23 inhibitors
AgentRoughly what proportion of people are clear or nearly clear (PASI 90) in the first 6 months?What is the likelihood of staying on this treatment for more than 1 year?
Guselkumab“44%”“85–90% chance”
Risankizumab“51%”“Not known at present”
Tildrakizumab“32%”“Not known at present”
Network meta-analyses: anti-IL-23 agents, adverse events, and short-term and long-term PASI 90
Drug survival and switching risk with IL-23 inhibitors compared with other biologics
Limitations of current therapies
Summary: undertreatment, route of administration, persistence, and access
  • Undertreatment: from 2003 through 2011, 23.6% to 35.5% of people with moderate psoriasis and 9.4% to 29.7% with severe psoriasis were untreated, 52.3% of those with psoriasis were dissatisfied with their treatment, and among those treated, 29.5% with moderate and 21.5% with severe psoriasis received topical agents alone. Of an estimated 1.7 million insured U.S. patients with moderate to severe psoriasis, 1 million (59%) were not treated in the preceding year, 807,000 had lapsed treatment, and 547,000 were treatment-naive; 40.9% were receiving therapy in the 12 months up to September 2012, and 22.5% of those treated received a biologic. In another study, more than 80% of psoriasis patients with ≥ 4 palms body surface area received no treatment or topical treatment only, and 45% had not seen a physician in a year.
  • Route of administration: respondents in one preference study were willing to accept a reduction from approximately 70% to 40% in the proportion achieving clear or almost-clear skin to avoid injections at home and use a topical treatment. In a survey of 178 patient and 43 dermatologist respondents, both groups preferred oral to injectable treatments for moderate disease when attributes were held equal, and patients with higher needle fear were more likely to favor an oral treatment. Biologics are available only by injection or infusion. In the joint AAD-NPF phototherapy guideline, narrowband UVB is recommended 3 times weekly in the treatment phase, and travel to a phototherapy center can be a limiting factor.
  • Persistence and switching: a meta-analysis of fifty-five studies estimated the proportions adherent and persistent to biological therapy at 0.61 (95% CI 0.48–0.73) and 0.63 (0.57–0.68), highest for ustekinumab and lowest for etanercept. Among 7997 biologic-treated people, switch rates were 14.4% at 12 months and 26.0% at 24 months; IL-23 inhibitors had the lowest risk of switching, with 8.5% for risankizumab and 15.7% for guselkumab over 24 months. The British Association of Dermatologists decision aid, drawing on UK real-world data, gives the likelihood of staying on treatment for more than 1 year as 67–73% for etanercept, 74–76% for adalimumab, 84–86% for ustekinumab, and 85–90% for guselkumab. Of 8,710 biologic-treated people, 11.5% switched and 31.1% discontinued, and switchers had higher adjusted total health care costs than nonswitchers (mean difference $10,120).
  • Access: inability to obtain adequate insurance coverage was among the top reasons for discontinuing biological agents. Insurance plans in the USA often require patients to try and fail other treatments first (step therapy), a process that “often delays access to medically necessary treatments”. Several labels limit the indicated population: cyclosporine to severe, recalcitrant plaque psoriasis after failure of at least one systemic therapy or when other systemic therapies are contraindicated or not tolerated, brodalumab to patients who have failed to respond or lost response to other systemic therapies and only through a REMS program, and adalimumab and infliximab to patients for whom other systemic therapies are medically less appropriate.
Summary: efficacy of oral agents relative to biologics, safety warnings, and monitoring
  • Efficacy in network meta-analyses: in a network meta-analysis of 204 studies with 67,889 randomized participants, anti-IL17, anti-IL12/23, anti-IL23, and anti-TNF-alpha biologics showed a higher proportion of participants reaching PASI 90 than non-targeted and targeted systemic agents. At class level, the PASI 90 RR for anti-IL17 treatment was 3.20 versus TYK-2 inhibitors, 4.01 versus non-targeted systemic treatments, and 5.82 versus phosphodiesterase-4 inhibitors. Deucravacitinib and risankizumab were more effective than apremilast, and ciclosporin and methotrexate were superior to apremilast for PASI 90. A second network meta-analysis, of 60 trials, estimated PASI 90 at 10 to 16 weeks from baseline at 12.1% for apremilast and 11.4% for dimethyl fumarate, against 17.9% for etanercept, 43.7% for adalimumab, 43.9% for ustekinumab, 70.8% for ixekizumab, and 71.6% for risankizumab-rzaa. A review states that deucravacitinib was superior to apremilast and inferior to risankizumab.
  • Limits of the comparative evidence: the network meta-analysis evidence is limited to induction therapy (outcomes from 8 to 24 weeks after randomisation), its participants had a mean age of 44.4 years and a baseline PASI of 20.5, and its serious adverse event analyses rested on a very low number of events. The guideline group of the EuroGuiDerm-adapted German S3 guideline stated it was not able to sufficiently differentiate recommendation levels for individual agents on PASI 90 and serious adverse events alone.
  • Conventional oral agents: methotrexate achieved PASI 75 in 35.5% of patients against 79.6% with adalimumab, and acitretin 50 mg/d achieved PASI 75 in 23% after 8 weeks. Cyclosporine, methotrexate, and acitretin are described as having “limited efficacy and/or are associated with serious side effects and major monitoring requirements”.
  • Safety warnings: the labels of adalimumab, etanercept, infliximab, and certolizumab pegol state an increased risk of serious infections that may lead to hospitalization or death, and the adalimumab label reports lymphoma and other malignancies in children and adolescents treated with TNF blockers. The JYLAMVO (methotrexate) label reports serious adverse reactions including death, and hepatotoxicity risk that generally occurs after a cumulative dose of 1.5 g or more. Cyclosporine can cause hypertension and nephrotoxicity (cyclosporine nephropathy in 18/86 [21%] of biopsied psoriasis patients). Acitretin must not be used by females who are pregnant or intend to become pregnant during therapy or for at least 3 years after discontinuation. Suicidal ideation and behavior, including completed suicides, have occurred with brodalumab, and bimekizumab carries a warning for suicidal ideation and behavior; oral candidiasis occurred in 19.3% with bimekizumab and 3.0% with secukinumab. The AAD-NPF biologics guideline recommends avoiding IL-17 inhibitors in patients with a personal history of or active IBD. With apremilast, depression was reported in 1.3% vs. 0.4% with placebo and weight decrease of 5%-10% in 12% vs. 5%, and diarrhea and nausea each occurred in 17%. The deucravacitinib label warns of infections, CPK elevation and rhabdomyolysis, and triglyceride elevations, and a review describes deucravacitinib as the only JAK or TYK2 inhibitor indicated for psoriasis that “does not have a boxed warning”. Class 1 topical corticosteroids are limited to up to 4 weeks, and tachyphylaxis may occur with use beyond 12 weeks.
  • Screening and monitoring: deucravacitinib requires evaluation for active and latent tuberculosis before treatment and periodic evaluation of serum triglycerides; for icotrokinra, tuberculosis evaluation is considered based on clinical judgement and live vaccines are avoided. The adalimumab label directs monitoring of all patients for active tuberculosis during treatment, even if the initial latent test is negative; cyclosporine requires frequent monitoring of serum creatinine; the EuroGuiDerm-adapted guideline group monitors methotrexate with transaminases; and periodic assessment of suicidal ideation is recommended with brodalumab. Apremilast has no requirement for laboratory monitoring.
Injection burden and preference for oral administration
Network meta-analysis evidence limited to induction-phase outcomes and trial populations
Place in treatment, anticipated use, and care setting
Summary: severity definitions and candidacy for systemic therapy
  • The German S3 guideline adapted from EuroGuiDerm (Nast et al.) defines mild psoriasis as “BSA ≤ 10 and PASI ≤ 10 and DLQI ≤ 10” and moderate to severe psoriasis as “(BSA > 10 or PASI > 10) and DLQI > 10”. Mild disease is upgraded to moderate-to-severe by major involvement of visible areas or the scalp, involvement of the genitals, palms, or soles, onycholysis or onychodystrophy of at least two fingernails, pruritus leading to scratching, or recalcitrant plaques. Criteria for particularly severe psoriasis include PASI ≥ 20, DLQI ≥ 15, rapid deterioration, and severe involvement of the hands and/or feet, scalp, face, nails, or genitals.
  • The most preferred statement reported by Strober et al. classifies patients as candidates for topical therapy or candidates for systemic therapy; the latter meet at least one of three criteria: body surface area >10%, disease involving special areas, or failure of topical therapy.
  • The National Psoriasis Foundation classifies a patient as having mild psoriasis, managed with topical therapies, or moderate-to-severe psoriasis, which makes the patient a candidate for advanced therapies, including phototherapy and modern systemic treatments; it states that current systemic treatments include oral and biologic therapies.
  • The deucravacitinib label indicates it for moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy, the icotrokinra label for the same population and for pediatric patients 12 years of age and older who weigh at least 40 kg, and the apremilast label for adults with plaque psoriasis who are candidates for phototherapy or systemic therapy. Trials PSO-1 and PSO-2 of the icotrokinra label defined moderate-to-severe plaque psoriasis as IGA score ≥3, PASI score ≥12, and BSA involvement ≥10%.
Summary: guideline positions on first systemic therapy and oral agents
  • EuroGuiDerm-adapted German S3 guideline (Nast et al.): when systemic treatment is initiated for the first time, the guideline suggests a biologic with a first-line label or deucravacitinib, especially for psoriasis of particular severity. It bases this on the disease burden of particularly severe psoriasis and on the results of the Cochrane review, and its classification of first-line and second-line agents follows the approved indications in the summary of product characteristics.
  • In the EuroGuiDerm-adapted guideline's summary of the Cochrane network meta-analysis (Nast et al.), infliximab, the anti-IL-17 drugs, and the anti-IL-23 drugs except tildrakizumab were significantly more likely to reach PASI 90 than ustekinumab, three anti-TNF alpha agents, and deucravacitinib, and no significant difference was shown between apremilast and ciclosporin or methotrexate. Sbidian et al. state that deucravacitinib and risankizumab were more effective than apremilast and that ciclosporin and methotrexate were superior to apremilast for reaching PASI 90.
  • AAD-NPF guideline on systemic nonbiologic therapies (Menter et al.): the guideline states that apremilast “is recommended for the treatment of moderate to severe psoriasis in adults” and describes it as an appropriate choice for patients who prefer to avoid frequent injections and laboratory monitoring and are willing to accept a slower onset of skin clearance and a lower likelihood of clearing. It also recommends methotrexate for moderate to severe psoriasis in adults and cyclosporine for severe, recalcitrant psoriasis.
  • Preference for oral therapy: among 397 respondents, avoiding injections in favor of oral or topical treatment was more important to patients than some improvements in efficacy. The Alumis corporate presentation states “75% Patients prefer orals over injectables”.
Summary: oral agents, head-to-head evidence, and the comparative evidence for envudeucitinib
  • Oral agents with a U.S. label: deucravacitinib 6 mg once daily; apremilast 30 mg twice daily after a 5-day titration, or the extended-release tablet 75 mg once daily; and icotrokinra 200 mg once daily upon waking on an empty stomach, whose market introduction date is 2026-03-18 in the California HCAI new prescription drugs file. The FDA accepted the zasocitinib NDA under Priority Review, with a PDUFA target action date in the first quarter of calendar year 2027.
  • Deucravacitinib versus apremilast: at week 16, PASI 75 was achieved by 58.4% with deucravacitinib, 35.1% with apremilast, and 12.7% with placebo in POETYK PSO-1, and by 53.0%, 39.8%, and 9.4% in POETYK PSO-2.
  • Icotrokinra versus deucravacitinib: in Trial PSO-1 of the icotrokinra label, week 16 PASI 90 was achieved by 171 of 311 (55%) icotrokinra and 91 of 307 (30%) deucravacitinib participants and PASI 100 by 97 (31%) and 34 (11%); in Trial PSO-2, week 16 PASI 90 was achieved by 184 (58%) and 111 (34%), while Stein Gold et al. report 184 of 322 (57%) for icotrokinra in ADVANCE 2. Through week 24 of ICONIC-ADVANCE 1 and 2, adverse events occurred in 359 of 632 (57%) icotrokinra and 411 of 634 (65%) deucravacitinib participants.
  • Zasocitinib: against deucravacitinib in LATITUDE Atlas (606 participants), week 16 PASI 100 was 36.5% (n=301) and 13.9% (n=303) and PASI 90 was 62.5% and 34.0%. Against apremilast at week 16, PASI 75 was 76% and 37% in LATITUDE PsO 3001 and 71% and 33% in LATITUDE PsO 3002 (Takeda press releases).
  • Oral agent versus biologic: in the open-label IMMpactful trial, funded by AbbVie, PASI 90 at week 16 was achieved by 57.3% with risankizumab and 22.9% with deucravacitinib.
  • Envudeucitinib: ONWARD1 and ONWARD2 compared envudeucitinib with placebo and apremilast, and STRIDE compared five envudeucitinib doses with placebo. The report holds no head-to-head trial of envudeucitinib against deucravacitinib, icotrokinra, zasocitinib, or a biologic. A review whose medical writing Alumis funded states that direct and formal indirect comparisons of oral agents “are not presently available”, and De Luca et al. state that the next-generation agents have been compared with placebo, apremilast, or deucravacitinib and have not been compared with IL-17 or IL-23 inhibitors. The Alumis corporate presentation compares PASI 100 rates of envudeucitinib (ONWARD1 and ONWARD2 at week 24), icotrokinra, and zasocitinib across trials and states that the results of this “retrospective post hoc cross-trial comparison may not be directly comparable”.
  • Care setting: Alumis states that its success will depend upon physicians specializing in the treatment of the targeted diseases prescribing its product candidates. A single-center retrospective review drew on referrals for specialty medications by dermatology providers for psoriasis or atopic dermatitis and on the specialty pharmacy patient management system. In the United States, access to dermatologists “is limited in many regions”, especially in underserved and rural communities.
Heterogeneity of treatment effect
Comorbidity-guided selection: inflammatory bowel disease, diabetes, cancer history, and latent tuberculosis

“In patients with psoriasis and IBD, we recommend preferentially using approved targeted therapies with documented efficacy in these conditions:” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“We suggest against the use of IL17 inhibitors in patients with inflammatory bowel disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“If alternative treatments are available, we suggest prescribing alternatives to MTX in patients with type 2 diabetes (with concomitant metabolic syndrome and/or signs of liver damage).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“For patients in remission of cancer for more than 5 years, we recommend selecting the most appropriate option for psoriasis treatment independent of the cancer.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“For patients with latent TB infection, we recommend choosing one of the following options:” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“acitretin, apremilast, ciclosporin, dimethyl fumarate, MTX, or phototherapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“We suggest against the use of deucravacitinib” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“in patients with latent TB infections unless there are no other suitable treatment options.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Due to lack of data concerning the reactivation risk” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Prior biologic or apremilast exposure: deucravacitinib real-world response through 52 and 104 weeks
Care management intervention strategies
Other product development or post-marketing obligations required by the FDA

Not applicable.

Ongoing post-approval monitoring

Not applicable.

Expected outcomes of therapy
Summary
  • Treatment goals: the EuroGuiDerm-adapted German S3 guideline (Nast et al.) names complete clearance as the fundamental goal of therapy and states that this goal is “not realistically achievable in all patients at this time”. A PASI 75 response is the minimum target at the end of the induction period, and PASI 90, an absolute PASI <2, or DLQI ≤ 1 is the desired goal. Goals are checked after 10 to 12 weeks for treatments with a fast onset of action and after 16 to 24 weeks for treatments with a slower onset, time frames that “may not always include the time of maximum therapeutic effect”.
  • Body surface area targets: Armstrong et al. set the acceptable response at 3 months as BSA 3% or less or BSA improvement of 75% or more from baseline, and the target response as BSA 1% or less at 3 months and at every 6-month maintenance evaluation.
  • Time to response: in an analysis of forty-five trials, the IL-17 inhibitors bimekizumab, ixekizumab, brodalumab, and secukinumab 300 mg were estimated to reach onset of PASI 90 response at approximately 6 to 8 weeks, the IL-23 inhibitors risankizumab and guselkumab at approximately 9–10 weeks, and the IL-12/23 inhibitor at 11–12 weeks; onset could not be estimated for tildrakizumab or for JAK and PDE4 inhibitors.
  • Quality of life by depth of response: in 16-week pooled data, the estimated proportions achieving DLQI 0/1 were 93.0% with PASI 100, 89.3% with a 95% PASI improvement, and 83.8% with a 90% PASI improvement, and the proportions with no itching (P-SIM = 0) were 61.7%, 50.8%, and 39.8%.
  • Maintenance with continuous biologic therapy: in LIMMitless, 661 of 897 enrolled participants completed the study, and at week 304, 86.0% achieved PASI 90, 54.2% PASI 100, 84.7% sPGA 0/1, and 76.3% DLQI 0/1 with risankizumab (modified nonresponder imputation). With secukinumab 300 mg, 168 participants entered the extension and 126 completed year 5; PASI 75/90/100 responses were 88.9%, 68.5%, and 43.8% at year 1 and 88.5%, 66.4%, and 41% at year 5, and DLQI 0/1 responses were 72.7% and 65.5%.
Time to response and timing of the treatment goal assessment